Form 4: Sutro Biopharma Executive Hans-Peter Gerber Reports Stock Option and RSU Awards
SEC Form 4 Filing
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.
Summary
- Hans-Peter Gerber, the Chief Scientific Officer of Sutro Biopharma, filed a Form 4 with the SEC.
- The filing reports the grant of stock options and restricted stock units (RSUs) to Gerber.
- Gerber was granted options to purchase 122,500 shares of common stock at an exercise price of $0.55 per share.
- These options vest monthly starting May 4, 2025, and will be fully vested by April 4, 2029.
- Gerber also received 113,750 RSUs, each representing the right to receive one share of Sutro Biopharma's common stock upon settlement.
- These RSUs vest annually, starting March 2, 2026, and will be fully vested by March 2, 2029.
- Both the options and RSUs are subject to Gerber's continued service to the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and contribution to the company's success.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.
Industry Context
Equity compensation is a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. The specific terms of the options and RSUs are typical for executive compensation packages.
Comparison to Industry Standards
- Equity grants are a standard component of compensation packages for executives in biotech companies like Sutro Biopharma.
- Comparable companies such as BioNTech, Moderna, and Genmab also utilize stock options and RSUs to incentivize their leadership teams.
- The vesting schedules and exercise prices are generally in line with industry norms, designed to align executive interests with long-term shareholder value.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/02/2026 | RSUs vest as to 1/4th of the total award annually beginning on this date. |
| 03/02/2029 | RSUs fully vested. |
| 04/04/2025 | Date of earliest transaction and grant date of stock options and RSUs. |
| 04/04/2029 | Stock options fully vested. |
| 04/04/2035 | Expiration date of stock options. |
| 04/08/2025 | Date of filing. |
Keywords
Form 4, Sutro Biopharma, Stock Options, RSUs, Hans-Peter Gerber, Beneficial Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.